Information for Connecticut Prescribers of Prescription Drugs

Zepbound[™] (tirzepatide) injection

- Connecticut Public Act No. 23-171 requires "pharmaceutical representatives" (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

Product:

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST ¹
Zepbound™	tirzepatide injection	2.5 MG/0.5 ML	Pen	4	0002-2506-80	\$1059.87
		5 MG/0.5 ML	Pen	4	0002-2495-80	\$1059.87
		7.5 MG/0.5 ML	Pen	4	0002-2484-80	\$1059.87
		10 MG/0.5 ML	Pen	4	0002-2471-80	\$1059.87
		12.5 MG/0.5 ML	Pen	4	0002-2460-80	\$1059.87
		15 MG/0.5 ML	Pen	4	0002-2457-80	\$1059.87

In adult patients with obesity and overweight, a reduction in body weight was observed with ZEPBOUND™ irrespective of race or ethnicity.²

See Prescribing Information, including Boxed Warnings.

Zepbound[™] and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

PP-LU-US-0974 11/2023 © Lilly USA, LLC 2023 All rights reserved.

¹ Source: AnalySource[®]. Accessed on 11/08/2023. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2023. http://www.fdbhealth.com/policies/drug-pricing-policy/.

² US Zepbound Prescribing Information.